Leigh C J, Palechek P L, Knutson J R, McCarthy J B, Cohen M B, Argenyi Z B
Department of Pathology, The University of Iowa, Iowa City 52242-1009, USA.
Hum Pathol. 1996 Dec;27(12):1288-94. doi: 10.1016/s0046-8177(96)90339-1.
CD44 is an integral membrane glycoprotein that is a principal receptor for hyaluronan and plays a role in cell-extracellular matrix interactions. Recent studies of melanomas in mouse models have suggested that increased CD44 expression by these tumors may relate to metastatic potential. Immunohistochemical expression of CD44 (standard [s] and variant [v6]) in benign and malignant nevomelanocytic lesions was assessed in formalin-fixed, paraffin-embedded tissue and was correlated with histological parameters and prognostic factors. Cases included benign nevi (three junctional, four compound, five intradermal, five blue, six Spitz, one deep penetrating), architecturally disordered (dysplastic) nevi (three, and primary (22) and metastatic melanomas (eight). All of the benign lesions showed diffuse and essentially uniform membrane staining of CD44s in nevomelanocytic cells, regardless of lesion size, depth, or extent of dermal involvement. In contrast, semiquantitative analysis (0 to 3+) of the primary melanomas showed heterogeneous and decreased staining of CD44s, which inversely correlated with lesion size (-0.569) and depth of invasion (-0.622 and -0.617 for Breslow's depth and Clark's level, respectively). These results were significant at P < .05. CD44s expression in metastases paralleled that of their respective primaries. None of the benign nevomelanocytic lesions showed CD44v6 staining. In contrast, all of the malignant nevomelanocytic lesions showed cytoplasmic staining of the tumor cells. Pretreatment with chondroitinase did not alter CD44s staining. CD44s expression by immunohistochemical determination is uniform in benign nevomelanocytic lesions. Malignant melanomas show decreased, heterogeneous staining that inversely correlates with increasing size, depth, and level of invasion. CD44 expression may be a prognostic indicator in malignant melanomas. Tumor staining with anti-chondroitin sulfate monoclonal antibodies suggests that CD44s may be expressed as a chondroitin sulfate proteoglycan in primary melanomas.
CD44是一种整合膜糖蛋白，是透明质酸的主要受体，在细胞与细胞外基质的相互作用中发挥作用。最近对小鼠模型黑色素瘤的研究表明，这些肿瘤中CD44表达的增加可能与转移潜能有关。在福尔马林固定、石蜡包埋的组织中评估了CD44（标准型[s]和变异型[v6]）在良性和恶性痣细胞性病变中的免疫组织化学表达，并将其与组织学参数和预后因素相关联。病例包括良性痣（3例交界痣、4例复合痣、5例皮内痣、5例蓝色痣、6例Spitz痣、1例深部穿透性痣）、结构紊乱（发育异常）痣（3例）以及原发性（22例）和转移性黑色素瘤（8例）。所有良性病变在痣细胞中均显示CD44s弥漫且基本均匀的膜染色，与病变大小、深度或真皮受累范围无关。相比之下，原发性黑色素瘤的半定量分析（0至3+）显示CD44s染色异质性降低，且与病变大小（-0.569）和浸润深度（Breslow深度和Clark分级分别为-0.622和-0.617）呈负相关。这些结果在P<0.05时具有统计学意义。转移灶中CD44s的表达与其各自的原发灶相似。所有良性痣细胞性病变均未显示CD44v6染色。相比之下，所有恶性痣细胞性病变均显示肿瘤细胞的胞质染色。用软骨素酶预处理并未改变CD44s染色。通过免疫组织化学测定，CD44s在良性痣细胞性病变中的表达是均匀的。恶性黑色素瘤显示染色降低、异质性，且与大小、深度和浸润分级的增加呈负相关。CD44表达可能是恶性黑色素瘤的一个预后指标。用抗硫酸软骨素单克隆抗体进行肿瘤染色表明，CD44s在原发性黑色素瘤中可能以硫酸软骨素蛋白聚糖的形式表达。
